Incidence of DHTR in patient
Reading File
Finding Sources
Searching PubMed
"delayed hemolytic transfusion reaction" incidence
Reading File
Reading File
Reading File
Searching PubMed
"delayed hemolytic transfusion reaction" incidence rate
Reading File
Finding Sources
Reading File
In india
Searching PubMed
"delayed hemolytic transfusion reaction" India
Searching the Web
incidence DHTR delayed hemolytic transfusion reaction India statistics
Reading Web Page
incidence DHTR India transfusion
Reading Article
I now have solid Indian-specific data. Here is a comprehensive answer:
Incidence of DHTR in India
Key Indian Study - Direct Incidence Data
The most relevant Indian data comes from a prospective study conducted at Madras Medical College, Chennai (a regional testing center for South India), published in the Journal of Applied Medical Sciences (2022):
- Study period: June 2020 - May 2022
- Total transfusions monitored: 49,450 PRBC and whole blood units
- DHTR cases found: 9
- DSTR cases found: 1
- Calculated incidence of DHTR: 1 in 8,200 transfusions (1:8,200)
- Calculated incidence of DSTR: 1 in 49,450 transfusions
This figure is notably lower than global estimates (1:500 to 1:10,000), which the authors attribute largely to underreporting and lack of post-transfusion antibody screening - a widespread limitation in developing countries including India.
Clinical Profile in That Indian Cohort
| Feature | Finding |
|---|---|
| Onset | 6/10 cases within 5 days; 3/10 cases on days 7-10; 1 case detected on day 13 |
| Drop in Hb | All 9 DHTR cases had decreased Hb; 2 cases had Hb < 4 g/dL |
| Hyperbilirubinemia | 7 out of 10 cases |
| LDH rise | 4 out of 10 cases |
| Reticulocytopenia | 2 out of 10 cases |
Indian Case Series - Sickle Cell Disease (2025)
A recent Indian case series (Anwar et al., Asian Journal of Transfusion Science, 2025 - PMID: 40837991) from an Indian center reported DHTR with alloimmunization in sickle cell disease patients, including one case of hyperhemolysis syndrome (HS), where post-transfusion Hb fell below pre-transfusion levels. All three patients were DAT positive with multiple alloantibodies. High-dose corticosteroids and IVIG were effective treatments.
Why Indian Incidence Data Is Likely Underestimated
- No routine post-transfusion antibody screening - most centers do not test patients after transfusion
- Limited immunohematology infrastructure - very few regional testing centers exist; the Madras Medical College center is one of very few
- Subtle symptoms often attributed to the underlying disease (e.g., thalassemia, sickle cell disease)
- Lack of hemovigilance reporting systems - India does not have a national hemovigilance system equivalent to SHOT (UK) or the FDA system (USA)
- High burden of hemoglobinopathies (sickle cell disease, beta-thalassemia) in India - these patients are at much higher risk of DHTR due to repeated transfusions and alloimmunization
Comparison: India vs. Global Incidence
| Source / Population | DHTR Incidence |
|---|---|
| South India (Madras MMC, 2020-22) | 1:8,200 transfusions |
| Global general estimate | 1:500 to 1:10,000 |
| Goldman-Cecil Medicine | ~1:32,000 transfusions |
| Tietz / Rosen's combined DHTR+DSTR | ~1:1,500 to 1:2,500 transfusions |
| Sickle cell disease patients (global) | ~11% of transfusions (Barash Clinical Anesthesia) |
Key Takeaway
India lacks a robust national-level DHTR surveillance system. The only published prospective Indian figure is 1:8,200 from a South India tertiary center, but the true incidence is almost certainly higher due to systematic underdetection. High-risk groups in India - particularly patients with sickle cell disease and thalassemia who receive repeated transfusions - face significantly elevated DHTR risk, and the call for comprehensive immunohematology laboratories and hemovigilance programs across India is well-recognized in the literature.
This is a shared conversation. Sign in to Orris to start your own chat.